A Study of Oral Methylnaltrexone (MNTX) for the Treatment of Opioid-Induced Constipation in Subjects With Chronic, Non-Malignant Pain

Trial Profile

A Study of Oral Methylnaltrexone (MNTX) for the Treatment of Opioid-Induced Constipation in Subjects With Chronic, Non-Malignant Pain

Completed
Phase of Trial: Phase III

Latest Information Update: 05 Sep 2017

At a glance

  • Drugs Methylnaltrexone bromide (Primary)
  • Indications Constipation
  • Focus Registrational; Therapeutic Use
  • Sponsors Salix Pharmaceuticals
  • Most Recent Events

    • 05 Sep 2017 According to Salix Pharmaceuticals media release, data from this trial will be presented at PAINWeek 2017.
    • 20 May 2017 Results presented at the 36th Annual Scientific Meeting of the American Pain Society.
    • 19 Jul 2016 According to Valeant Pharmaceuticals and Progenics Pharmaceuticals, Inc media release, the U.S. Food and Drug Administration has approved RELISTOR (methylnaltrexone bromide) Tablets for the treatment of opioid-induced constipation (OIC) in adults with chronic non-cancer pain.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top